BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37161765)

  • 1. Diffuse large B-cell lymphoma at risk of secondary CNS involvement: The inefficacy of intravenous high-dose methotrexate CNS prophylaxis and the importance of baseline cerebrospinal fluid analysis.
    Bennett R; Ruskova A; Coomarasamy C; Theakston E; Berkahn L; Jackson S; Christophers M; Wong S; Issa S
    Am J Hematol; 2023 Jul; 98(7):1070-1079. PubMed ID: 37161765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma.
    Puckrin R; El Darsa H; Ghosh S; Peters A; Owen C; Stewart D
    Am J Hematol; 2021 Jul; 96(7):764-771. PubMed ID: 33811794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial.
    Gleeson M; Counsell N; Cunningham D; Chadwick N; Lawrie A; Hawkes EA; McMillan A; Ardeshna KM; Jack A; Smith P; Mouncey P; Pocock C; Radford JA; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Ann Oncol; 2017 Oct; 28(10):2511-2516. PubMed ID: 28961838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of standardized prophylactic high-dose and intrathecal methotrexate for DLBCL with a high risk of CNS relapse.
    Akimoto M; Miyazaki T; Takahashi H; Saigusa Y; Takeda T; Hibino Y; Tokunaga M; Ohashi T; Matsumura A; Teshigawara H; Suzuki T; Teranaka H; Nakajima Y; Matsumoto K; Hashimoto C; Fujimaki K; Fujita H; Sakai R; Fujisawa S; Nakajima H
    Int J Hematol; 2024 Feb; 119(2):164-172. PubMed ID: 38233702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model for Predicting Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma and Discussion of Prophylaxis Measures.
    Cui JY; Liu YF; Gao B; Mi L; Deng LJ; Zhu J; Hou SL
    World Neurosurg; 2023 Nov; 179():e387-e396. PubMed ID: 37652134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of high-dose methotrexate prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma: a multicenter analysis.
    Fang Y; Su N; Ma S; Cai J; Zhong L; Li W; Huang H; Li Z; Huang H; Xia Y; Liu P; Guo L; Li Z; Wu Y; Tian X; Wang J; Zhang Y; Cai Q
    Ann Hematol; 2022 Mar; 101(3):595-605. PubMed ID: 34985557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylaxis strategies containing high dose intravenous methotrexate on preventing CNS relapse for patients with diffuse large B-cell lymphoma at intermediate to high risk: A study based on 12 cohorts in the rituximab era.
    Zhang N; Xu D; Liu B; Shi X; Xie X; Wang Z
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109299. PubMed ID: 36252471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.
    Wilson MR; Eyre TA; Kirkwood AA; Wong Doo N; Soussain C; Choquet S; Martinez-Calle N; Preston G; Ahearne M; Schorb E; Moles-Moreau MP; Ku M; Rusconi C; Khwaja J; Narkhede M; Lewis KL; Calimeri T; Durot E; Renaud L; Øvlisen AK; McIlroy G; Ebsworth TJ; Elliot J; Santarsieri A; Ricard L; Shah N; Liu Q; Zayac AS; Vassallo F; Lebras L; Roulin L; Lombion N; Manos K; Fernandez R; Hamad N; Lopez-Garcia A; O'Mahony D; Gounder P; Forgeard N; Lees C; Agbetiafa K; Strüßmann T; Htut TW; Clavert A; Scott H; Guidetti A; Barlow BR; Tchernonog E; Smith J; Miall F; Fox CP; Cheah CY; El Galaly TC; Ferreri AJM; Cwynarski K; McKay P
    Blood; 2022 Apr; 139(16):2499-2511. PubMed ID: 34995350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.
    Kansara R
    Curr Treat Options Oncol; 2018 Sep; 19(11):52. PubMed ID: 30203318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic HD-MTX for CNS prophylaxis in high-risk DLBCL patients: a prospectively collected, single-center cohort analysis.
    Lee K; Yoon DH; Hong JY; Kim S; Lee K; Kang EH; Huh J; Park CS; Lee SW; Suh C
    Int J Hematol; 2019 Jul; 110(1):86-94. PubMed ID: 31115880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery.
    Wilson MR; Eyre TA; Martinez-Calle N; Ahearne M; Parsons KE; Preston G; Khwaja J; Schofield J; Elliot J; Mula Kh A; Shah N; Cheung CK; Timmins MA; Creasey T; Linton K; Smith J; Fox CP; Miall F; Cwynarski K; McKay P
    Blood Adv; 2020 Aug; 4(15):3586-3593. PubMed ID: 32761231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent-based analysis.
    Jeong H; Cho H; Kim H; Chae H; Lee JB; Lee K; Kim S; Lee SW; Ryu JS; Kim KW; Chae EJ; Huh J; Park CS; Yoon DH; Suh C
    Blood Adv; 2021 Apr; 5(8):2142-2152. PubMed ID: 33881464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: A network meta-analysis.
    Lin Z; Chen X; Liu L; Zeng H; Li Z; Xu B
    Crit Rev Oncol Hematol; 2022 Aug; 176():103756. PubMed ID: 35809794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse.
    Bobillo S; Joffe E; Sermer D; Mondello P; Ghione P; Caron PC; Hamilton A; Hamlin PA; Horwitz SM; Kumar A; Matasar MJ; Batlevi CL; Moskowitz A; Noy A; Owens CN; Palomba ML; Straus D; von Keudell G; Dogan A; Zelenetz AD; Seshan VE; Younes A
    Blood Cancer J; 2021 Jun; 11(6):113. PubMed ID: 34135307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors Influencing Physician Discretion to Administer CNS Prophylaxis in Diffuse Large B Cell Lymphoma: A Single Institution Retrospective Study.
    Hino C; Lacy C; Brothers J; Cao H; Mirshahidi H; Park K; Akhtari M
    Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):764-771. PubMed ID: 37482525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limited efficacy of high-dose methotrexate to prevent the central nervous system relapse in patients with IVLBCL.
    Terao T; Tsushima T; Ikeda D; Fukumoto A; Kamura Y; Kuzume A; Tabata R; Miura D; Narita K; Takeuchi M; Matsue K
    Leuk Lymphoma; 2022 Dec; 63(14):3394-3401. PubMed ID: 36111741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.
    Orellana-Noia VM; Reed DR; McCook AA; Sen JM; Barlow CM; Malecek MK; Watkins M; Kahl BS; Spinner MA; Advani R; Voorhees TJ; Snow A; Grover NS; Ayers A; Romancik J; Liu Y; Huntington SF; Chavez JC; Saeed H; Lazaryan A; Raghunathan V; Spurgeon SE; Ollila TA; Del Prete C; Olszewski A; Ayers EC; Landsburg DJ; Echalier B; Lee J; Kamdar M; Caimi PF; Fu T; Liu J; David KA; Alharthy H; Law J; Karmali R; Shah H; Stephens DM; Major A; Rojek AE; Smith SM; Yellala A; Kallam A; Nakhoda S; Khan N; Sohail MA; Hill BT; Barrett-Campbell O; Lansigan F; Switchenko J; Cohen J; Portell CA
    Blood; 2022 Jan; 139(3):413-423. PubMed ID: 34570876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.
    Tomita N; Takasaki H; Ishiyama Y; Kishimoto K; Ishibashi D; Koyama S; Ishii Y; Takahashi H; Numata A; Watanabe R; Tachibana T; Ohshima R; Hagihara M; Hashimoto C; Takemura S; Taguchi J; Fujimaki K; Sakai R; Motomura S; Ishigatsubo Y
    Leuk Lymphoma; 2015 Mar; 56(3):725-9. PubMed ID: 24913502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study.
    Perry C; Ben Barouch S; Goldschmidt N; Sarid N; Herishanu Y; Shvidel L; Bairey O; Lavi N; Horowitz N; Avigdor A; Lebel E; Sofer O; Ram R; Avivi I
    Am J Hematol; 2019 Sep; 94(9):992-1001. PubMed ID: 31211434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.